Results 291 to 300 of about 2,386,530 (346)

Multifunctional Gold Nanocluster‐Based PROTAC System for Targeted Degradation of Phosphorylated Tau and Modulation of Neuroinflammation in Alzheimer's Disease

Advanced Functional Materials, EarlyView.
We present a novel proteolysis‐targeting chimera (PROTAC) system conjugated to lipoic acid gold nanoclusters (PLANC), designed to degrade pTau, regulate inflammatory signaling, and effectively traverse the blood‐brain barrier (BBB). PLANC degraded pTau at various phosphorylation sites, with mechanistic studies confirming proteasome‐mediated degradation
Sarah Nevins, Callan D. McLoughlin, Wan‐Kyu Ko, Hye Kyu Choi, Brandon Conklin, Joshua B. Stein, Yannan Hou, Hongwon Kim, Rohan Khulbe, Ki‐Bum Lee   +9 more
wiley   +1 more source

Cytokine release syndrome triggered by programmed death 1 blockade (sintilimab) therapy in a psoriasis patient: A case report. [PDF]

World J Clin Cases
Zhou MH, Ye MF, Zhang ZX, Tao F, Zhang Y.   +4 more
europepmc   +1 more source

Efficacy comparison of fruquintinib, regorafenib monotherapy or plus programmed death-1 inhibitors for microsatellite stable metastatic colorectal cancer. [PDF]

World J Gastrointest Oncol
An TQ, Qiu H, Zhou QB, Zong H, Hu S, Lian YG, Zhao RH.   +6 more
europepmc   +1 more source

Peripheral blood lymphocyte subpopulations as predictive biomarkers for first-line programmed death 1 inhibitors efficacy in esophageal squamous cell carcinoma: A retrospective study. [PDF]

Medicine (Baltimore)
Sun J, Gan W, Yao J, Han Z, Fang Z, Xiong W, Li D, Wu J, Cao L, Zhu L.   +9 more
europepmc   +1 more source

Roles of programmed death-1 and muscle innate lymphoid cell-derived interleukin 13 in sepsis-induced intensive care unit-acquired weakness. [PDF]

J Cachexia Sarcopenia Muscle
Akama Y, Park EJ, Satoh-Takayama N, Ito A, Kawamoto E, Gaowa A, Matsuo E, Oikawa S, Saito M, Inoue S, Akimoto T, Suzuki K, Shimaoka M.   +12 more
europepmc   +1 more source

Synergistic action of gemcitabine and celecoxib in promoting the antitumor efficacy of anti-programmed death-1 monoclonal antibody by triggering immunogenic cell death. [PDF]

Transl Cancer Res
Zhu X, Zhang W, Yu Z, Yang X, Li L, Chen C, Djumanazarov T, Piquemal D, Yusupbekov AA, Zheng Y.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Transarterial chemoembolisation enhances programmed death‐1 and programmed death‐ligand 1 expression in hepatocellular carcinoma

Histopathology, 2020
Immunotherapies represent a new alternative therapeutic approach for hepatocellular carcinomas (HCCs), and have shown promising results when used in combination therapy.
A. Montasser, A. Beaufrère, F. Cauchy, M. Bouattour, O. Soubrane, M. Albuquerque, V. Paradis   +6 more
semanticscholar   +3 more sources

Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma

Current Opinion in Oncology, 2015
The development of 'immune checkpoint inhibitors' or drugs targeting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) axis has been a stunning success of cancer immunotherapy. This review provides a timely overview of the biology and function of the PD-1 pathway and discusses the rationale for therapeutic inhibition of this pathway in ...
Chan Yoon, Cheah, Nathan H, Fowler, Sattva S, Neelapu   +2 more
openaire   +3 more sources

Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer

Human Antibodies, 2022
In numerous studies related to tumor prognosis, programmed death-ligand 1 (PD-L1) has been identified as a biomarker. This work aimed to determine the prognostic importance of PD-L1 in breast cancer. We searched electronic databases such as PubMed, Google scholar, home pages of publishing groups, medical, clinical, and pharmaceutical sciences journals,
Imtiaz Mahmood, Tahir, Abdur, Rauf, Huma, Mehboob, Samia, Sadaf, Muhammad Shaiful, Alam, Fadia, Kalsoom, Abdelhakim, Bouyahya, Aicha, El Allam, Nasreddine, El Omari, Saad, Bakrim, Muhammad, Akram, Syed Kashif, Raza, Talha Bin, Emran, Yahia N, Mabkhot, Gokhan, Zengin, Marina, Derkho, Suray, Natalya, Mohammad Ali, Shariati   +17 more
openaire   +2 more sources

Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death‐Ligand 1 Blockade Responses

Hepatology, 2021
Biliary tract cancer (BTC) exhibits diverse molecular characteristics. However, reliable biomarkers that predict therapeutic responses are yet to be discovered.
Jihoon G. Yoon, Min Hwan Kim, Mi Jang, Hoguen Kim, H. Hwang, C. Kang, Woo-Jung Lee, B. Kang, Choong-kun Lee, Min Goo Lee, H. Chung, Hye Jin Choi, Y. N. Park   +12 more
semanticscholar   +1 more source